193 related articles for article (PubMed ID: 30181619)
1. Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients.
Chen W; Zhang X; Zhang W; Peng C; Zhu W; Chen X
Sci Rep; 2018 Sep; 8(1):13182. PubMed ID: 30181619
[TBL] [Abstract][Full Text] [Related]
2. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.
Zhou X; He Y; Kuang Y; Li J; Zhang J; Chen M; Chen W; Su J; Zhao S; Liu P; Chen M; Shen M; Chen X; Zhu W; Chen X
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28146080
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.
Campalani E; Allen MH; Fairhurst D; Young HS; Mendonca CO; Burden AD; Griffiths CE; Crook MA; Barker JN; Smith CH
Br J Dermatol; 2006 Feb; 154(2):345-52. PubMed ID: 16433808
[TBL] [Abstract][Full Text] [Related]
4. Acitretin revisited in the era of biologics.
Booij MT; Van De Kerkhof PC
J Dermatolog Treat; 2011 Apr; 22(2):86-9. PubMed ID: 20673152
[TBL] [Abstract][Full Text] [Related]
5. A review of acitretin for the treatment of psoriasis.
Lee CS; Li K
Expert Opin Drug Saf; 2009 Nov; 8(6):769-79. PubMed ID: 19998529
[TBL] [Abstract][Full Text] [Related]
6. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis.
van de Kerkhof PC; Cambazard F; Hutchinson PE; Haneke E; Wong E; Souteyrand P; Damstra RJ; Combemale P; Neumann MH; Chalmers RJ; Olsen L; Revuz J
Br J Dermatol; 1998 Jan; 138(1):84-9. PubMed ID: 9536227
[TBL] [Abstract][Full Text] [Related]
7. [Acitretin].
Dubertret L
Ann Dermatol Venereol; 2011 Dec; 138(12):829-32. PubMed ID: 22137620
[No Abstract] [Full Text] [Related]
8. Association of IL36RN mutations with clinical features, therapeutic response to acitretin, and frequency of recurrence in patients with generalized pustular psoriasis.
Zhu T; Jin H; Shu D; Li F; Wu C
Eur J Dermatol; 2018 Apr; 28(2):217-224. PubMed ID: 29619998
[TBL] [Abstract][Full Text] [Related]
9. The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis.
Chen W; Wu L; Zhu W; Chen X
Per Med; 2018 May; 15(3):181-188. PubMed ID: 29843550
[TBL] [Abstract][Full Text] [Related]
10. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety.
Borghi A; Corazza M; Bertoldi AM; Caroppo F; Virgili A
Acta Derm Venereol; 2015 Mar; 95(3):332-6. PubMed ID: 24978351
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and drug survival of acitretin in psoriasis: a retrospective observational study.
Chularojanamontri L; Silpa-Archa N; Wongpraparut C; Limphoka P
Int J Dermatol; 2019 May; 58(5):593-599. PubMed ID: 30548592
[TBL] [Abstract][Full Text] [Related]
12. Is Oral Chinese Herbal Medicine Beneficial for Psoriasis Vulgaris? A Meta-Analysis of Comparisons with Acitretin.
Zhang CS; Yang L; Zhang AL; May BH; Yu JJ; Guo X; Lu C; Xue CC
J Altern Complement Med; 2016 Mar; 22(3):174-88. PubMed ID: 26919330
[TBL] [Abstract][Full Text] [Related]
13. An updated review of acitretin--a systemic retinoid for the treatment of psoriasis.
Pang ML; Murase JE; Koo J
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):953-64. PubMed ID: 18624682
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
Yu C; Fan X; Li Z; Liu X; Wang G
Eur J Dermatol; 2017 Apr; 27(2):150-154. PubMed ID: 28400341
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
Dogra S; Jain A; Kanwar AJ
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e305-11. PubMed ID: 22816881
[TBL] [Abstract][Full Text] [Related]
16. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
Caproni M; Antiga E; Melani L; Volpi W; Del Bianco E; Fabbri P
J Clin Immunol; 2009 Mar; 29(2):210-4. PubMed ID: 18763027
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy of acitretin therapy for nail psoriasis.
Tosti A; Ricotti C; Romanelli P; Cameli N; Piraccini BM
Arch Dermatol; 2009 Mar; 145(3):269-71. PubMed ID: 19289755
[TBL] [Abstract][Full Text] [Related]
19. Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result.
Ricceri F; Pescitelli L; Tripo L; Bassi A; Prignano F
Dermatol Ther; 2013; 26(1):77-8. PubMed ID: 23384024
[TBL] [Abstract][Full Text] [Related]
20. Plexin B2 tissue expression and related gene polymorphisms in psoriasis and their relation to NB-UVB and Acitretin therapy.
Hegazy EM; Taieb MAE; Hassan MH; Ibrahim AK; El-Din EA; Ibrahim HM
Arch Dermatol Res; 2024 May; 316(5):162. PubMed ID: 38734848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
